Generics (UK) Ltd trading as Mylan and another v Yeda Research and Development Company

Patent – Infringement. Two claims of a patent directed to a dosage regimen for the administration of glatiramer acetate for the treatment of relapsing forms of multiple sclerosis were novel over a piece of prior art, but were also obvious over the prior art. While the two claims were invalid, it was not appropriate for the court to grant an Arrow declaration.

Category: